Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

被引：0

作者：

Rubinstein, A. ^{[1
,2
]}

Wasserman, R. L. ^{[3
]}

Melamed, I. ^{[4
]}

Stein, M. ^{[5
]}

McCoy, B. ^{[6
]}

Engl, W. ^{[6
]}

Leibl, H. ^{[6
]}

Gelmont, D. ^{[7
]}

Schiff, R. I. ^{[7
]}

Grossman, W. J. ^{[7
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY 10467 USA

[2] Montefiore Hosp, Bronx, NY USA

[3] DallasAllergyImmunol, Dallas, TX USA

[4] IMMUNOe, Centennial, CO USA

[5] Allergy Associates Palm Beaches, N Palm Beach, FL USA

[6] Baxter BioSci, Vienna, Austria

[7] Baxter BioSci, Westlake Village, CA USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2011年 / 127卷 / 02期

关键词：

D O I：

10.1016/j.jaci.2010.12.848

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：AB213 / AB213

页数：1

共 50 条

[41] REAL-WORLD USE OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IG) (IGHY; HYQVIA) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISORDERS (PIDD)
Rosenbach, Kevin P.
Hughes, Stephanie M.
Rozen, Leon
JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 271 - 272
[42] Recombinant human hyaluronidase facilitates dispersion of subcutaneously administered Gammagard liquid and enables administration of a full monthly bose in a single site to patients with immunodeficiency diseases
Melanned, I. R.
Stein, M. R.
Wasserman, R. L.
Leibl, H.
Engl, W.
Yocum, R. C.
Schiff, R. I.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S83 - S83
[43] A PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE (rHuPH20)-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN (IG) (IGHY) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Sommer, C.
England, J.
Jakobsen, J.
Reeve, R.
Oh, M. S.
Ngo, L. Y.
Tobias, K.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 235 - 235
[44] Modeled Economic Impact of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% with Recombinant Human Hyaluronidase (IGHy) or Intravenous Immunoglobulin (IGIV) in Primary Immunodeficiency (PI) Patients
Iyer, Ravi
Luo, Michelle
Li-McLeod, Josephine
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 397 - 397
[45] PHARMACOKINETICS (PK) OF ORAL LAMIVUDINE ADMINISTERED ALONE WITH ORAL ZIDOVUDINE (ZDV) IN ASYMPTOMATIC PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION
HORTON, CM
YUEN, G
MIKOLICH, DM
FISHER, A
RANA, K
MYDLOW, P
DUDLEY, MN
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 198 - 198
[46] RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNO GLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PI): LONG TERM SAFETY, EFFICACY, AND TOLERABILITY.
Wasserman, R. L.
Stein, M.
Melamed, I.
Kobrynski, L.
Grant, J. A.
Gupta, S.
Engl, W.
Leibl, H.
Yel, L.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A89 - A89
[47] MECHANISM OF ACTION AND LONG-TERM TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNE GLOBULIN 10% (HYQVIA [IGHY]) IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
Melamed, Isaac
Gupta, Sudhir
Sehinovych, Ihor
Hermann, Corinna
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
MUSCLE & NERVE, 2018, 58 : S50 - S50
[48] Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (Ighy) In Patients With Primary Immunodeficiency (Pi)
Stein, Mark
Wasserman, Richard
Melamed, Isaac
Rubinstein, Arye
Engl, Werner
Leibl, Heinz
McCoy, Barbara
Gelmont, David
Schiff, Richard
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 354 - 354
[49] Long-Term Safety and Pharmacokinetics of Facilitated Subcutaneous Infusion of Immune Globulin (Human) 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients with Primary Immunodeficiency (PI)
Melamed, Isaac
Wasserman, Richard
Stein, Mark
Rubenstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
Gelmont, David
Schiff, Richard
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 363 - 363
[50] OPEN PROSPECTIVE TRIAL INVESTIGATING PHARMACOKINETICS, TOLERABILITY AND SAFETY OF A NEW 10% HUMAN IMMUNOGLOBULIN FOR INTRAVENOUS INFUSION (IVIG) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE
Krivan, G.
Koenigs, C.
Bernatowska, E.
Marodi, L.
Erdos, M.
Salama, A.
Linde, R.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 154 - 154

← 1 2 3 4 5 →